Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | HTR2C | P28335 | 6/20 | 0.44 |
| ▸ | HTR2B | P41595 | 6/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.44 |
| ▸ | FLT1 | P17948 | 2/20 | 0.44 |
| ▸ | FLT4 | P35916 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | ABL2 | P42684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30819532 | 0.84 | SLC6A4 (0.53) | HTR2CHTR2BSLC6A4HTR6 | |
| SCHEMBL21984779 | 0.81 | NOS1 (0.54) | EGFRHTR2CHTR2BFGFR1FLT1 | |
| SCHEMBL13652112 | 0.81 | MAOA (0.40) | EGFRKDR | |
| SCHEMBL4302370 | 0.78 | DRD4 (0.54) | KDR | |
| SCHEMBL2124399 | 0.78 | ACHE (0.49) | — | |
| SCHEMBL4302361 | 0.78 | DRD4 (0.54) | KDR | |
| SCHEMBL2056311 | 0.76 | SIGMAR1 (0.50) | — | |
| SCHEMBL30933736 | 0.75 | OPRL1 (0.46) | EGFRHTR2CHTR2BFGFR1FLT1 | |
| SCHEMBL420188 | 0.74 | SIGMAR1 (0.38) | EGFRHTR2CHTR2BFGFR1FLT1 | |
| SCHEMBL13861972 | 0.73 | POLB (0.48) | EGFRFGFR1FLT1FLT4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318939-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318939-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8318939-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-11-27 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120252761-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-04 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| US-8278450-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-02 | — | — | US | disclosed |
| CN-101356172-B | Kinase inhibitors | TAKEDA SAN DIEGO INC | 2012-06-13 | — | — | CN | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156557-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| EP-1931669-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| WO-2008054956-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| WO-2008045834-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| US-20070117816-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-24 | — | — | US | disclosed |
| WO-2007044779-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117816-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | EGFR 349/4885HTR2C 2969/4885HTR2B 3485/4885 |
| US-20090156557-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | EGFR 378/4885HTR2C 3480/4885HTR2B 4254/4885 |
| US-20120252761-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | EGFR 378/4885HTR2C 3480/4885HTR2B 4254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.